Close
Help




JOURNAL

Clinical Medicine Insights: Oncology

Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab

Submit a Paper


Clinical Medicine Insights: Oncology 2012:6 287-303

Review

Published on 16 Aug 2012

DOI: 10.4137/CMO.S8511


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Oncology

Abstract

Hormone ablation therapy (HALT) for breast or prostate cancer accelerates the development of osteoporosis in both men and women by causing estrogen deficiency, which increases the risk for fracture by promoting bone resorption mediated by osteoclasts. Denosumab, a fully human monoclonal antibody that inhibits osteoclast formation and function, increases bone mass in patients undergoing hormone ablation therapy. In the HALT study of 1,468 men with prostate cancer on androgen-deprivation therapy, denosumab significantly reduced the risk of new vertebral fractures, increased bone mineral density (BMD), and reduced markers of bone turnover. In a study of 252 women with breast cancer undergoing adjuvant aromatase inhibitor (AI) therapy, denosumab increased BMD at 12 and 24 months, overall and in all patient subgroups. The overall rates of adverse events were similar to placebo. Clinicians should consider fracture risk assessment and therapies such as denosumab to increase bone mass in patients on hormone ablation therapy who are at high risk for fracture.



Downloads

PDF  (1.18 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML




What Your Colleagues Say About Clinical Medicine Insights: Oncology
It is an honor that my manuscript was accepted by the Clinical Medicine Insights: Oncology.  The comments from reviewers were professional, the emails from the editor were friendly, and the procedure was very quick.  I will submit further manuscripts to Clinical Medicine Insights: Oncology in the near future.
Dr Cheng Tan (Hamamatsu University School of Medicine, Shizuoka, Japan)
More Testimonials

Quick Links


New article and journal news notification services